Connect with us

Media OutReach

Uni-Bio Science Joins Forces with WMU NERC and Ouhai District Government to Build Growth Factor Innovation Ecosystem and Accelerate Regenerative Medicine Strategy Layout

Published

on

HONG KONG SAR – EQS Newswire – 30 December 2025 – Uni-Bio Science Group Limited (“Uni-Bio Science Group”, “Uni-Bio” or “the Group”) is pleased to announce the official signing of a tripartite strategic cooperation agreement in Wenzhou, Zhejiang, with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University (“WMU NERC”) and the People’s Government of Ouhai District, Wenzhou. The parties also explored the subsequent co-establishment of the “Uni-Bio – WMU Joint Innovation Laboratory for Translational Medicine.” This collaboration marks a key step for Uni-Bio in deeply integrating with a national-level research platform and a regional industrial ecosystem. Through a synergistic “government-university-enterprise” model, the three parties will focus on the core regenerative medicine field of growth factors to establish an end-to-end innovation system spanning basic research, clinical translation, and industrial application. This represents a milestone for the Group in consolidating its R&D pipeline and accelerating its strategic execution.

Strategic cooperation signing ceremony group photo

Focusing on Growth Factor Frontiers, Unleashing “1+1>2” Clinical and Market Potential

Growth factors are key signaling molecules that regulate cell proliferation, migration, and tissue repair, representing some of the most transformative bioactive substances in regenerative medicine. Both EGF (Epidermal Growth Factor) and FGF (Fibroblast Growth Factor) have demonstrated significant efficacy across major indications, including wound healing, ophthalmic diseases, and metabolic disorders, underscoring their substantial market potential.

Uni-Bio possesses deep expertise in the EGF field, with its flagship products GeneTime® and GeneSoft® achieving large-scale production and nationwide commercial coverage. Concurrently, under the leadership of Academician Li Xiaokun, the WMU NERC has been a global pioneer in FGF drug R&D, having successfully translated several Class I New Drugs – including Recombinant Human Basic Fibroblast Growth Factor – and has accumulated substantial clinical data and authoritative expert consensus in trauma and metabolic diseases.

Building on this foundation, the three parties will initiate collaborative research on combined EGF/FGF therapies for key areas, including burns, dermatology, and ophthalmology. The goal is to unlock powerful therapeutic synergies, develop superior combination products and advance delivery systems, set new treatment benchmarks, and establish a leadership position in shaping this multi-billion Yuan sector.

Empowered by Academician Leadership & Platform, Creating a Fast Track from R&D to Production

The WMU NERC is an independent legal entity established by Wenzhou Medical University based on the national-level platform, the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations. It undertakes downstream functions including engineering technology research and development, transformation of scientific and technological achievements, and technical services. In synergistic collaboration with the National Key Laboratory for Macromolecular Drugs and Large-Scale Preparation, which focuses on upstream basic research, the Center has built a next-generation growth factor drug pipeline targeting multiple systems such as metabolism and dermatology. Through the ongoing research of Academician Li Xiaokun’s team, the Center has achieved internationally leading breakthroughs in key technologies, including long-acting Modification, targeted delivery, and aerosol inhalation.

The planned “Uni-Bio – WMU Joint Innovation Laboratory for Translational Medicine” will conduct in-depth research into the synergistic mechanisms of Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair. It aims to develop novel compound formulations and drug delivery systems targeting conditions such as endocrine diseases represented by non-alcoholic steatohepatitis (NASH), respiratory diseases represented by asthma, as well as bone tissue repair. These diseases affect a large global patient population, yet there remains a significant unmet clinical need for innovative therapies. Through this collaboration, it is expected to address treatment gaps in multiple specific indications, further unlocking clinical and commercial value in the broad chronic disease market.

The “Government-University-Enterprise ” Trinity, Systematically Strengthening Full-Chain Capabilities

This collaboration extends beyond technological synergy to ecosystem co-development. The People’s Government of Ouhai District, Wenzhou, is a key facilitator and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core platform, the “China Gene Valley,” will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages – from R&D and pilot-scale testing to industrialization.

For Uni-Bio, this tripartite cooperation delivers threefold empowerment:

  • R&D Front: Direct access to the National Engineering Research Center’s source innovation and core technologies, elevating the starting point of R&D.
  • Clinical Front: Collaboration with Wenzhou Medical University’s affiliated hospital network to accelerate clinical validation and indication expansion.
  • Commercialization Front: Leveraging the advanced manufacturing capabilities and regional policy benefits of the China Gene Valley to ensure efficient project implementation and facilitate market access.

This strategic partnership is a crucial step in the Group’s pursuit of its vision “To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life” Moving forward, the Group will continue to deepen collaborations with national scientific institutions and local governments, driving the translation of more cutting-edge research into clinical and market value. This will further consolidate and enhance its comprehensive competitiveness and leadership in regenerative medicine.
Hashtag: #Uni-BioScience

The issuer is solely responsible for the content of this announcement.

About Uni-Bio Science:

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2001(Stock Code: 00690.HK). The Group is committed to powering the advancement of regenerative medicine with next-generation synthetic biology and complex peptide innovation. Focusing on four core research areas—muscular-skeletal regeneration, skin regeneration, ocular regeneration, and ENT regeneration—the Group has built a diversified product pipeline encompassing innovative biologics, high-value generic drugs, and medical aesthetics. The Group operates GMP-compliant production bases in Beijing, Dongguan, and Shenzhen, with fully integrated capabilities spanning R&D, manufacturing, and commercial sales. Uni-Bio Science Group is dedicated to becoming a global leader in regenerative medicine, redefining how science restores and extends human life.

About the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University:

The WMU NERC is an independent legal entity established by Wenzhou Medical University based on the national-level platform, the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations. It undertakes downstream functions including engineering technology research and development, transformation of scientific and technological achievements, and technical services. Under the leadership of Chinese Academy of Engineering Academician Li Xiaokun, the Center has long been engaged in foundational research and novel drug discovery for cell growth factor drugs, holding a globally leading position. It brings together top-tier scientific teams, undertakes major national science and technology projects, and has successfully developed a series of innovative FGF drugs with independent intellectual property rights. Through synergistic collaboration with the National Key Laboratory for Macromolecular Drugs and Large‑Scale Preparation, the Center forms a complete innovation chain from source discovery and key technological breakthroughs to industrial translation. As the important R&D engine of the China Gene Valley, it continuously promotes the incubation and translation of several original new drug candidates, including a long-acting FGF21 variant.

About the People’s Government of Ouhai District, Wenzhou:
The People’s Government of Ouhai District, Wenzhou, is a key facilitator and supporter of this strategic cooperation, committed to building a first-class biomedical industry ecosystem. Its core platform, the “China Gene Valley,” will provide comprehensive spatial support and specialized policy assistance for the cooperative projects across all stages – from R&D and pilot-scale testing to industrialization. Through specialized industrial policies, “full-cycle escort” services, and clinical resource coordination, Ouhai District empowers the implementation and growth of innovation projects, serving as a vital driver for regional biomedical industry innovation and development.

Media OutReach

Hong Kong Company Formations Surge 40.5% in 2025, Outpacing Regional Competitors

Published

on

Air Corporate data reveals 9 in 10 founders incorporated in Hong Kong do so remotely, driven by a 20% surge in Middle Eastern entrepreneurs seeking cost-effective operational alternatives to Dubai.

HONG KONG SAR – Media OutReach Newswire – 15 May 2026 – Air Corporate registered a 40.5% increase in Hong Kong incorporations in 2025, with the first quarter of 2026 already up 48% year-over-year. This data indicates that Hong Kong is reasserting itself as the leading Asian jurisdiction for company formation, fueled by a new wave of remote founders from the Middle East, North Africa, and Europe.

The prevailing narrative over the past five years suggested that Singapore was eclipsing Hong Kong; however, recent incorporation volumes challenge this. According to city-wide official figures cited by Vivian, Founder of Air Corporate, approximately 195,000 companies were registered in Hong Kong in 2025, compared to around 77,000 in Singapore.

“There was a lot of fuss about Singapore taking over Hong Kong as preferred jurisdiction over the last few years, but for 2025 alone, around 195,000 companies were formed in HK, vs around 77,000 for Singapore,” said Vivian. While city-wide registrations rose roughly 35% in 2025, incorporations at Air Corporate specifically grew by 40.5%. Vivian added, “With a 35% increase in the number of companies registered in 2025, Hong Kong is definitely back in the game as the top jurisdiction to start a company.”

The reality of Hong Kong company formation is increasingly global, lean, and founder-led. Nine in ten founders incorporated in Hong Kong with Air Corporate do not live there.

Key demographic and operational insights from Air Corporate’s client base include:

  • Approximately 90% of founders operate remotely from abroad, while 10% or less are based in Hong Kong.
  • Entrepreneurs aged 35 to 44 represent the largest age cohort at 38%, demonstrating that Hong Kong attracts founders in their prime career years rather than just younger digital nomads.
  • Serial entrepreneurs make up 60% of Air Corporate’s client mix, utilizing Hong Kong as an operational base for multiple companies, while first-time founders account for the remaining 40%.
  • A total of 89% of new companies are launched by solo founders (58%) or small teams of two to five individuals (31%).
  • Mainland China, Hong Kong, Turkey, India, the UAE, Australia, France, and Morocco rank among the top source markets for these founders.

Furthermore, 73% of new Hong Kong incorporations are directly tied to physical goods trade with China. This consists of e-commerce and dropshipping businesses (38%) and the trading of goods (35%). The recovery of in-person trade flows, including events, such as the Canton Fair and various industrial fairs, is pulling foreign founders back into the Greater China orbit and establishing Hong Kong as the natural entry point and financial layer over the world’s largest manufacturing base.

Air Corporate’s data recorded a 20% year-over-year growth in founders originating from the Middle East. This shift highlights a reverse migration where founders previously incorporated in Dubai are now choosing Hong Kong. Based on Vivian’s observations, founders often arrive in Dubai expecting fast incorporation and low costs, but discover that incorporation and maintenance are significantly more expensive than in Hong Kong, and banking remains difficult. Consequently, many founders move to Hong Kong after 12 to 24 months in the UAE, a trend accelerated by the Hong Kong government’s strategic outreach to the region.

For lean, remote-first businesses, speed-to-market is a critical factor. A founder located anywhere in the world can incorporate in Hong Kong and open a working bank account in approximately 7 days using digital banking partners. Currently, 90% of Air Corporate’s clients utilize these digital banking partners.

“Hong Kong and Singapore are the only places in Asia where you can set up your company, get a corporate account, and be in business in less than a week,” concluded Vivian.

Air Corporate is a service provider facilitating company formation and incorporation in Hong Kong for serial entrepreneurs, first-time founders, and remote-first business owners operating globally.

Media Inquiries
To learn more about Hong Kong company formation, visit Air Corporate’s website or contact their team directly.

Hashtag: #AirCorporate

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Natural Diamonds Sparkle on The Red Carpet at The 2026 Met Gala Celebrating “Costume Art”

Published

on

Today’s biggest stars express individuality and confidence with natural diamonds

NEW YORK, US – Media OutReach Newswire – 15 May 2026 – The 2026 Met Gala celebrating “Costume Art” took place May 4th at the Metropolitan Museum of Art in New York City, bringing together leading figures from across the globe for an unforgettable evening. These tastemakers showcased the most classic, refined and distinctive diamond jewelry looks of the season. Below, A Diamond is Forever highlights the standout trends from the event.

Desert diamonds

Desert diamonds emerged as a striking throughline on the Met Gala carpet, with a range of hues in distinctive settings taking focus.

Rihanna led the trend in a pair of exceptionally rare old Moghul Golconda fancy brown-yellow diamond earrings by Glenn Spiro, featuring two pear-shaped natural diamonds totaling 51.9 carats. Doja Cat offset her all nude look with a pair of large Leviev Diamonds floral-shaped earrings while Paloma Elsesser made a statement in a 29.5-carat diamond necklace by Bernard James, centered around a 15-carat fancy light yellow pear-shaped natural diamond. Cara Delevingne wore a De Beers London Forces of Nature High Jewelry ring, featuring marquise yellow diamonds set as eyes, while Emma Chamberlain opted for yellow and white diamond earrings by Chopard, underscoring the continued allure of warm diamond hues.

Magnificent Diamond Earrings

A wide variety of captivating silhouettes defined the natural diamond earrings on the Met Gala carpet. Zoë Kravitz delivered a modern twist with oversized diamond flower earrings by Jessica McCormack. Chase Sui Wonders opted for Jean Schlumberger by Tiffany & Co. Sea Fan earrings, bringing an element of sculptural artistry to the look. Gracie Abrams selected gently dangling Chanel earrings, adding understated fluidity, while Connor Storrie selected simple hoop earrings from Tiffany & Co., reinforcing the clean and enduring appeal of natural diamonds.

Standout Diamond Moments

Natural diamonds appeared in personal, unconventional and eye-catching ways, offering moments of surprise and awe. Power couple Beyoncé and Jay-Z embodied this trend with Beyoncé wearing Chopard’s Queen of Kalahari necklace, named after the rare 342-carat diamond that provided 23 stones for Chopard’s Garden of Kalahari collection. Jay-Z contributed to the narrative with a vintage diamond brooch by Briony Raymond worn at the collar as an unexpected placement that underscored the piece’s versatility. Isha Ambani made the styling of diamonds an art form in itself, wearing her own diamond jewelry featuring approximately 150 carats of old mine-cut diamonds, including a three-strand necklace and chandelier earrings, while also incorporating diamonds sewn directly into the bodice of her sari to represent significant moments in her life.

Together, these looks highlighted a shift toward natural diamonds as vessels of personal expression, styled with intention, individuality, and a sense of the unexpected.

Hashtag: #MetGala #RedCarpet #ADiamondisForever #NaturalDiamonds #Diamonds





The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Turn Your Savings into a Front-Row Experience: HL Bank Singapore Offers Exclusive Passes to AsiaTop Music Festival 2026

Published

on

The premier music festival will play host to 16 K-pop, regional and Malaysian stars including, in performance order: Day 1 – NexT1DE, Aina Abdul, Belle Sisoski, Win Metawin, NMIXX, WINNER, DAESUNG, KUN. Day 2 – Uriah See, Firdhaus, Butterbear, 82MAJOR, STAYC, CRAVITY, TWS, CxM

SINGAPORE – Media OutReach Newswire – 14 May 2026 – Your next major K-pop experience is just a savings goal away as HL Bank Singapore (“HLB Singapore”) bridges the gap between financial wellness and the front row. In an exclusive collaboration designed for the ultimate music enthusiast, the bank is offering fans the chance to secure a pair of sought-after AsiaTop Music Festival 2026 tickets, valued at up to RM1,098 (approx. S$355), simply by growing their wealth.

HL Bank Singapore is giving music fans the chance to redeem exclusive passes to the AsiaTop Music Festival 2026, featuring top Asian acts, through its iSavings Reward Campaign.

This unique initiative stems from the regional synergy between Hong Leong Bank (“HLB”) and Tencent Music Entertainment Group (JOOX and QQ Music). By aligning with Visit Malaysia Year and Visit Selangor Year 2026, HLB is transforming the traditional banking experience into a gateway for premium entertainment. Scheduled for 30 and 31 May 2026 at the iconic Sepang International Circuit, the festival promises a high-octane weekend featuring an elite lineup of Asian superstars, including the largest K-pop showcase in the ASEAN region.

Securing a spot at the heart of the action has been streamlined through the iSavings Reward Campaign, running from 9 May 2026 to 18 May 2026. To participate, fans first decide on their preferred festival experience, selecting either a pair of Standard Passes with a S$5,000 deposit or the high-energy, nearer-to-the-stars Rockzone Passes with a S$8,282 deposit for their chosen day.

Once a tier is selected, customers can register by depositing the qualifying funds into an iSavings account via FAST or Links transfer. To validate their entry, customers must include the specific Comment Code, such as PALLIR1 for Day 1 Rockzone, within the funds transfer description. The qualifying balance must be maintained within the account for a six-month (182 days) earmarked period.

With only 88 pairs of tickets available for this exclusive campaign, the stakes are high. Allocation is limited to 22 pairs per day for each ticket category and will be awarded strictly on a first-come, first-served basis. Fans are encouraged to act quickly to ensure their savings work as hard as they do while securing a premier seat at the musical event of the year.

For full terms & conditions, and further details, please visit: www.hlbank.com.sg/AsiaTop2026

Hashtag: #HLBankSingapore

The issuer is solely responsible for the content of this announcement.

HL Bank Singapore

HL Bank Singapore is the Singapore branch of Hong Leong Bank Berhad, a leading digital-centric Malaysia-based financial services institution with a rooted heritage in the country spanning over 120 years. Operating under a Full Bank Licence in Singapore, HL Bank offers a comprehensive range of financial services to our business, retail and high networth customers through our 4 core business segments – Business & Corporate Banking, Personal Financial Services, Private Wealth Management and Global Markets.

Continue Reading

Trending